BioTech 365

MARCH 17, 2021

Global Growth Hormone Deficiency Clinical Trials Review, H1 2021 Report – ResearchAndMarkets.com Global Growth Hormone Deficiency Clinical Trials Review, H1 2021 Report – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Growth Hormone Deficiency – Global Clinical Trials Review, H1, 2021” clinical trials has (..)

Hormones 40

Hormones Clinical Trials Clinical Trials Trials 40

Medical Xpress

DECEMBER 8, 2022

In patients with hormone receptor (HR)-positive, HER2-negative tumors resistant to aromatase inhibitors, addition of the investigational AKT inhibitor capivasertib to fulvestrant (Faslodex) doubled the median progression-free survival compared with placebo plus fulvestrant in the phase III CAPItello-291 clinical trial, according to results presented (..)

Hormones 73

Hormones HR Clinical Trials Clinical Trials 73

Medical Xpress

DECEMBER 8, 2022

The next-generation selective estrogen receptor degrader (SERD) camizestrant improved progression-free survival, compared with fulvestrant (Faslodex), in patients with hormone receptor-positive, HER2-negative breast cancer in the phase II SERENA-2 trial, according to results presented at the San Antonio Breast Cancer Symposium, held December 6-10, (..)

Hormones 70

Hormones Trials 70

AuroBlog - Aurous Healthcare Clinical Trials blog

APRIL 23, 2024

Semaglutide (sold as Wegovy and Ozempic) and tirzepatide (sold as Zepbound and Mounjaro) are the most well known in the class of drugs that mimic hormones to reduce feelings of hunger. Drugs like Ozempic are very effective at helping most people who take them lose weight. But does weight come back when you stop using […]

Doctors 156

Doctors Doctor Hormones Drugs 156

AuroBlog - Aurous Healthcare Clinical Trials blog

DECEMBER 17, 2023

New research by our team has identified sensitivity to a hormone made in abundance by the developing pregnancy, GDF15, […] Sickness in pregnancy, or hyperemesis gravidarum, is common and is thought to affect seven out of ten women at some time in their pregnancy. But, until recently, very little has been known about why it happens.

Hormones 221

Hormones Research Development Clinical Trials 221

BioTech 365

NOVEMBER 18, 2021

TROPION-Breast01 Phase 3 Trial of Datopotamab Deruxtecan Initiated in Patients with Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer TROPION-Breast01 Phase 3 Trial of Datopotamab Deruxtecan Initiated in Patients with Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer TOKYO & … Continue reading →

Hormones 52

Hormones Trials 52

pharmaphorum

AUGUST 4, 2022

Two phase 3 trials of Merck & Co’s Keytruda in metastatic castration-resistant prostate cancer (CRPC) and advanced liver cancer have ended in failure, proving once again that cancer immunotherapy studies can be a hit-and-miss affair. The post Keytruda fluffs its lines in prostate, liver cancer trials appeared first on.

Trials 105

Trials Hormones Drugs Clinical Development 105

BioSpace

MARCH 18, 2024

The biotech Tuesday reported that 56% of patients taking paltusotine in a late-stage trial achieved the primary endpoint of IGF-1 levels for their rare hormonal disorder. An NDA submission is slated for later this year with a launch anticipated in 2025.

Hormones 113

Hormones Trials 113

Scienmag

SEPTEMBER 27, 2020

New study based on the early versus late intervention trial with estradiol data confirms benefit of hormone therapy in reducing multiple biomarkers of inflammation CLEVELAND, Ohio (September 28, 2020)–As one of the most common treatments for effectively managing menopause symptoms, hormone therapy (HT) is also known to provide multiple health (..)

Hormones 46

Hormones Trials Cardiology Medicine 46

pharmaphorum

OCTOBER 17, 2022

Bayer has added another clinical trial to its extensive phase 3 programme for oral neurokinin antagonist elinzanetant, hoping to show that it can treat vasomotor symptoms (VMS) in breast cancer patients. The post Bayer extends elinzanetant trials to include breast cancer appeared first on. There are around 2.3

Trials 110

Trials Hormones Clinical Trials Clinical Trials 110

The Pharma Data

DECEMBER 21, 2020

FDA Approves First Oral Hormone Therapy for Advanced Prostate Cancer. 21, 2020 — Orgovyx (relugolix) is now approved to treat advanced prostate cancer and is the first oral hormone therapy approved for this indication, the U.S. MONDAY, Dec. Food and Drug Administration announced Friday.

Hormones 52

Hormones FDA Approval Trials Drugs 52

Pharmaceutical Technology

MAY 15, 2023

The drug’s application was based on clinical data from the BRIGHT SKY program , which included the SKYLIGHT 1 (NCT04003155) and SKYLIGHT 2 (NCT04003142) trials. Prior to Veozah’s approval, available treatments for hot flashes included hormone replacement therapy, which consisted of either combined oestrogen and progestogen or oestrogen.

Hormones 244

Hormones FDA Approval Licensing Licensing 244

The Pharma Data

JUNE 12, 2022

Investigational phase 3 data for Sogroya ® ( somapacitan ) injection in children with growth hormone deficiency presented today at the ENDO 2022 Congress 1. Based on the results of the REAL 4 study, there is potential for a once-weekly option for children with growth hormone deficiency.”. cm/year, compared to 11.7

Hormones 52

Hormones Medicine Trials Production 52

Drug Discovery World

DECEMBER 9, 2022

A new type of targeted medicine has shown ‘remarkable’ benefits for patients with advanced breast cancer in a major Phase III clinical trial. . The drug capivasertib combined with hormone therapy doubled the time it took for cancer to progress in people with advanced forms of the most common type of breast cancer. . months to 7.2

Trials 52

Trials Hormones Drugs Genetics 52

AuroBlog - Aurous Healthcare Clinical Trials blog

JULY 17, 2023

The pill, called Opill – the brand name for the tablet formulation of norgestrel – is an oral contraceptive containing only progestin hormone, which helps prevent pregnancy […]

Hormones 185

Hormones Containment Branding Drugs 185

BioTech 365

DECEMBER 3, 2021

ARASENS trial with darolutamide in combination with docetaxel and androgen deprivation therapy meets primary endpoint of significantly increasing overall survival in patients with metastatic hormone-sensitive prostate cancer ARASENS trial with darolutamide in combination with docetaxel and androgen deprivation therapy meets … Continue reading (..)

Hormones 40

Hormones Trials 40

Pharma Times

JUNE 28, 2023

Trial involved over 450 women across Europe, Turkey and Canada who were unsuitable for hormone therapy - News - PharmaTimes

Hormones 116

Hormones Trials 116

XTalks

JANUARY 9, 2024

The thyroid plays a critical role in the body by producing hormones that regulate metabolism, heart rate and body temperature among others. Types of Thyroid Conditions There are several different thyroid conditions, with each affecting thyroid hormone production or the gland’s structure, leading to a range of health issues.

Hormones 105

Hormones Antibody Trials Production 105

Pharmaceutical Technology

JUNE 1, 2023

On 31 May, the FDA granted approval based on subgroup analysis of the Phase III PROpel trial (NCT03732820) in patients with BRCA mutations. Safety and tolerability were in line with that observed in prior trials and the known profiles of the medicines. Trials peaked at 115 in 2018 before declining to 91 last year.

FDA Approval 244

FDA Approval Hormones Trials Clinical Trials 244

pharmaphorum

MARCH 23, 2021

That’s looking increasingly likely thanks to the trial data just announced, which shows the drug significantly improved overall and progression-free survival compared with standard care in PSMA-positive metastatic castration-resistant prostate cancer. The five-year survival rate for patients with mCRPC is approximately 15%.

Trials 124

Trials Hormones Sales Regulation 124

Pharmaceutical Technology

JUNE 13, 2023

The combination therapy is intended to treat hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in adult patients, after recurrence or progression on or after an endocrine-based regimen.

HR 245

HR Hormones Trials Protein 245

The Pharma Data

DECEMBER 21, 2020

The Phase III study was conducted as an open-label trial with patients receiving either an Orgovyx pill daily or injections of Abbvie’s Lupron as an injection every three months. Because prostate cancer is fueled by testosterone production, both drugs decrease levels of the hormone in the body. .

Hormones 52

Hormones FDA Approval Drugs Production 52

AuroBlog - Aurous Healthcare Clinical Trials blog

SEPTEMBER 9, 2022

Millions around the world must inject the crucial hormone underneath their skin several times a day to keep their glucose levels in balance. The most effective way for people with diabetes to deliver insulin is also incredibly intrusive.

Insulin 200

Insulin Hormones Scientist Clinical Trials 200

BioTech 365

OCTOBER 5, 2020

NASDAQ: PBYI), a biopharmaceutical company, announced that efficacy results of neratinib in HER2-positive, hormone receptor-positive (HR+), early stage breast cancer (eBC) from the Phase III ExteNET trial were … Continue reading →

Hormones 52

Hormones HR Trials 52

Medical Xpress

NOVEMBER 11, 2022

A Monash University-led trial of a new drug known as Q-122 therapy significantly reduced the number and severity of hot flashes and night sweats in women who have been diagnosed with breast cancer. It also improved their sleep and had no serious adverse effects.

Hormones 98

Hormones Trials Drugs 98

pharmaphorum

APRIL 25, 2022

Roche revealed in its first-quarter results statement that giredestrant missed the mark in the phase 2 acelERA trial in advanced breast cancer, in what appears to be another blow to the emerging oral selective oestrogen receptor degrader (SERD) class.

Trials 68

Trials Hormones HR Sales 68

Pharmaceutical Technology

FEBRUARY 9, 2023

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. MK-0677 is active growth hormone secretagogue that acts on the growth hormone secretagogue receptor in the anterior pituitary to stimulate the release of growth hormone.

Hormones 100

Hormones Clinical Trials Clinical Trials Genetics 100

Medical Xpress

APRIL 28, 2023

However, this decline in quality of life was temporary and there were no clinically meaningful differences in quality of life between treatment arms by one year after the initiation of treatment.

Clinical Trials 71

Clinical Trials Clinical Trials Trials Hormones 71

AuroBlog - Aurous Healthcare Clinical Trials blog

DECEMBER 14, 2022

If you’re someone who has to deal with a period regularly, you’re probably all too familiar with just how much your energy levels can change throughout your cycle thanks to hormonal fluctuations.

Hormones 165

Hormones Clinical Trials Clinical Trials Clinical Research 165

BioSpace

OCTOBER 28, 2020

On October 14th, Amolyt Pharma announced the first dosing in its Phase I trial of AZP-3601 in healthy subjects, a momentous occasion capping off years of hard work in pre-clinical development. The drug aims to walk the biological tightrope in the management of hypoparathyroidism, a rare disease c.

Hormones 75

Hormones Development Clinical Development Trials 75

Medical Xpress

FEBRUARY 10, 2023

A prohibition against puberty blocking hormones and gender-affirming surgeries for minors in Florida was tightened further after a board overseeing doctors eliminated an exception for clinical trials Friday at the request of Florida Gov. Ron DeSantis' administration.

Doctors 94

Doctors Doctor Hormones Clinical Trials 94

AuroBlog - Aurous Healthcare Clinical Trials blog

JULY 10, 2023

Available through a collaboration with the consumer-initiated testing business of Quest Diagnostics and Proov, maker of at-home fertility and hormone tests, the Proov Confirm PdG test is the first and only FDA-cleared […]

Hormones 127

Hormones Clinical Trials Clinical Trials Trials 127

Pharmaceutical Technology

JULY 13, 2022

Orion discovered and developed ODM-208 to treat hormone-dependent cancers, such as prostate cancer. An oral, non-steroidal and selective CYP11A1 inhibitor, ODM-208 is currently being analysed in a Phase II trial in mCRPC patients. As per the agreement, the companies will jointly develop and market ODM-208.

Development 264

Development Hormones Production Marketing 264

pharmaphorum

MARCH 14, 2022

Shares in Sanofi were on the slide this morning after the drugmaker revealed that one of its top pipeline prospects – selective oestrogen receptor degrader (SERD) amcenestrant – stumbled in a mid-stage breast cancer trial. The post Sanofi takes a hit as hotly tipped breast cancer drug fails trial appeared first on.

Trials 63

Trials Hormones HR Drugs 63

XTalks

JANUARY 23, 2024

Pediatric growth hormone deficiency (PGHD) is one such condition, affecting a child’s growth and development. This rare endocrine disorder, characterized by inadequate secretion of growth hormone from the pituitary gland, has profound impacts on physical and sometimes cognitive development.

Development 72

Development Hormones Drugs Trials 72

XTalks

NOVEMBER 29, 2023

David Cameron, Chair of the Breast International Group (BIG) , we delve into the landscape of breast cancer research today, clinical trials and the incorporation of the patient voice in breast cancer research. Breakthroughs in Treatment BIG has been at the forefront of numerous clinical trials.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Research 52

Drug Discovery World

MAY 6, 2024

The company’s lead therapeutic peptide candidate is currently in a Phase III clinical trial for the treatment of hypoparathyroidism. Hypoparathyroidism is a rare condition defined by a deficiency of parathyroid hormone (PTH) that results in decreased calcium and elevated phosphorus levels in the blood.

Hormones 52

Hormones Clinical Trials Clinical Trials Trials 52